Lyra Therapeutics, Inc.
DelistedCIK 1327273fmd_1GEMW5TRVCQESDQ143S5GFWSAXManufacturing · Surgical & Medical Instruments & ApparatusTemplate: Standard
Coverage: Jan 01, 2019 to Dec 31, 2025, 28 periods
Latest annual · FY2025
Millions- Total revenues
- 0
- Operating income
- (31)
- Net income
- (29)
- Free cash flow
- (29)
Latest quarter · Q4 FY2025
Millions- Total revenues
- 0
- Operating income
- (7)
- Net income
- (7)
- Free cash flow
- (6)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- -33.7%
- Revenue, 5 yearsFY2020 to FY2025
- n/m
- Net income, 5 yearsFY2020 to FY2025
- n/m
Lyra Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $398,000 | $1.5 million | -74.1% | 10-K 2026-03-31 · proof |
| Operating income | -$31 million | -$96.3 million | 10-K 2026-03-31 · proof | |
| Net income | -$28.9 million | -$93.4 million | 10-K 2026-03-31 · proof | |
| Cash from operating activities | -$28.9 million | -$70 million | 10-K 2026-03-31 · proof | |
| Free cash flow | -$29 million | -$72.3 million | 10-K 2026-03-31 · proof | |
| Total assets | $36.1 million | $66.3 million | -45.6% | 10-K 2026-03-31 · proof |
| Total liabilities | $46.8 million | $54.8 million | -14.5% | 10-K 2026-03-31 · proof |
| Cash and cash equivalents | $15.9 million | $40.6 million | -60.8% | 10-K 2026-03-31 · proof |
- What was Lyra Therapeutics, Inc.'s revenue in fiscal 2025?
- Lyra Therapeutics, Inc. reported revenue of $398,000 for fiscal 2025 (the year ended Dec 31, 2025), against $1.5 million the year before (-74.1%). Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
- What was Lyra Therapeutics, Inc.'s operating income in fiscal 2025?
- Lyra Therapeutics, Inc. reported operating income of -$31 million for fiscal 2025 (the year ended Dec 31, 2025), against -$96.3 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
- What was Lyra Therapeutics, Inc.'s net income in fiscal 2025?
- Lyra Therapeutics, Inc. reported net income of -$28.9 million for fiscal 2025 (the year ended Dec 31, 2025), against -$93.4 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
- What was Lyra Therapeutics, Inc.'s cash from operating activities in fiscal 2025?
- Lyra Therapeutics, Inc. reported cash from operating activities of -$28.9 million for fiscal 2025 (the year ended Dec 31, 2025), against -$70 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
- What was Lyra Therapeutics, Inc.'s free cash flow in fiscal 2025?
- Lyra Therapeutics, Inc. reported free cash flow of -$29 million for fiscal 2025 (the year ended Dec 31, 2025), against -$72.3 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
- What are Lyra Therapeutics, Inc.'s total assets?
- As of Dec 31, 2025, Lyra Therapeutics, Inc. reported total assets of $36.1 million, against $66.3 million a year earlier (-45.6%). Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
- What are Lyra Therapeutics, Inc.'s total liabilities?
- As of Dec 31, 2025, Lyra Therapeutics, Inc. reported total liabilities of $46.8 million, against $54.8 million a year earlier (-14.5%). Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
- What are Lyra Therapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2025, Lyra Therapeutics, Inc. reported cash and cash equivalents of $15.9 million, against $40.6 million a year earlier (-60.8%). Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1327273&period_type=annual&limit=5"Information only, not investment advice.